LaunchTrends: Gilotrif (US) (Wave 3) | 2014
“LaunchTrends: Gilotrif Wave 3 (US)” is the third in a series of syndicated reports designed to track physician perception, uptake, and competitive environment regarding the newly launched non-small-cell lung cancer (NSCLC) drug Gilotrif (Boehringer Ingelheim’s afatinib). In this report, we measure the impact of this new agent on the metastatic NSCLC therapy market based on a blend of quantitative and qualitative primary research with U.S. medical oncologists. We focus on these physicians’ current awareness and perception of Gilotrif relative to other currently available therapies for metastatic NSCLC, their current and anticipated use of Gilotrif, and promotional activity of Gilotrif.
Related Market Assessment Reports
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
